Glp 1

3 articles

A symbolic bridge representing Medicare's temporary copay program for obesity drugs, connecting patients to vital medications.

Medicare's temporary $50 copay for obesity drugs like Zepbound

Starting July 1, 2026, eligible Medicare Part D beneficiaries will access branded obesity drugs like Zepbound for a $50 monthly copay, an unprecedented expansion of coverage set to expire just 18 mont

Dr. Evelyn Reed·June 8, 2026

A scientist in a futuristic lab examining a holographic display of a triple hormone receptor drug, representing Pfizer's new obesity treatment.

Cosmos & Physics

Pfizer advances monthly obesity drug targeting triple hormone receptors

Pfizer is advancing a monthly weight-loss injection, danuglipron, having announced positive early-stage data.

Dr. Evelyn Reed·June 7, 2026

A glowing, complex quintuple agonist molecule in a futuristic lab, representing a breakthrough in obesity and diabetes treatment.

Cosmos & Physics

New Quintuple Agonist Shows Promise for Obesity and Diabetes in Mice

In obese mice, a single experimental drug molecule, a GLP-1R GIPR PPAR quintuple agonist, led to greater weight loss and better blood sugar control than semaglutide (Ozempic) and a standard GLP-1/GIP

Dr. Evelyn Reed·May 18, 2026